Associated Papers
ERBB family fusions are recurrent and actionable oncogenic targets across cancer types.
Schubert L et al.
Frontiers in Oncology, 2023
37168365 (PubMed )
Supplement: Table_4.xlsx › EGFR_mutations
High prevalence of TP53 loss and whole-genome doubling in early-onset colorectal cancer.
Kim JE et al.
Experimental & Molecular Medicine, 2021
33753878 (PubMed )
Supplement: 12276_2021_583_MOESM1_ESM.zip › 210226_BJX6JPRP_EMM2020836R_Supplelemtary_table_merged__1_.xls › Supplementary_Table_3
Driver mutations in USP8 wild-type Cushing's disease.
Sbiera S et al.
Neuro-oncology, 2019
31222332 (PubMed )
Supplement: noz109_suppl_supplementary_material.pdf
ErbB polymorphisms: insights and implications for response to targeted cancer therapeutics.
Alaoui-Jamali MA et al.
Frontiers in Genetics, 2015
25699077 (PubMed )
Supplement: Table1.PDF
Discrepancies in cancer genomic sequencing highlight opportunities for driver mutation discovery.
Hudson AM et al.
Cancer Research, 2014
Select a paper to view details